Michael Wick

XenoSTART

XenoSTART is an industry-leading oncology translational research organization focused on the development and utilization of PDX models. Founded in 2007, XenoSTART was created in close collaboration with The START Center, an international cancer treatment and research organization. This partnership provides the unique ability to generate clinically-relevant XenoSTART patient-derived xenograft (XPDX) models. ​ Our diverse repository of XPDX (XenoSTART PDX) models are clinically annotated and include patient treatment history and outcome. The models are characterized through genomic profiling, histologic analysis, next generation sequencing, and in vivo drug sensitivity to relevant standards of care. Our models can accelerate preclinical discovery and drug development through the following turn-key services: In vivo PK/PD and efficacy studies In-licensing of models for proprietary studies Orthotopic and radiotherapy studies [collaboration with our partners] Ex vivo and organoid studies [collaboration with our partners] In vivo efficacy panel screens [indication or target focused] Cell line development Custom model development